ArticleTH open : companion journal to thrombosis and haemostasis2026
Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Disease without Pulmonary Hypertension: Prevalence and Clinical Impact in a Dutch Cohort.
Article in TH open : companion journal to thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disorder associated with venous thromboembolism (VTE) and chronic thromboembolic pulmonary hypertension (CTEPH). Current guidelines recommend APS screening in CTEPH patients. The exact prevalence of APS in both CTEPH and chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH) remains unclear. Although recently increasing attention has been directed toward treatment outcomes following pulmonary endarterectomy (PEA), other CTEPD without PH patients and those treated with alternative interventions, such as balloon pulmonary angioplasty or PH medication, remain insufficiently studied. This study aimed to assess the prevalence, lesion distribution, and outcomes of APS in CTEPH and CTEPD without PH. We retrospectively analyzed 259 patients diagnosed with CTEPH (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.